Correction: Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study

• Georg Schett,
• Warner Chen,
• Sheng Gao,
• Soumya D. Chakravarty,
• May Shawi,
• Frederic Lavie,
• Miriam Zimmermann,
• Mohamed Sharaf,
• Laura C. Coates,
• Stefan Siebert

Affiliations

Georg Schett

Department of Medicine 3 – Rheumatology and Immunology, Universitatsklinikum Erlangen

Warner Chen

Immunology, Janssen Research & Development, LLC

Sheng Gao

Immunology, Janssen Research & Development, LLC

Soumya D. Chakravarty

Immunology, Janssen Scientific Affairs, LLC

May Shawi

Immunology, Global Medical Affairs

Frederic Lavie

Immunology, Global Medical Affairs, Janssen Pharmaceutical Companies of Johnson & Johnson

Miriam Zimmermann

Immunology, Janssen Medical Affairs, LLC

Mohamed Sharaf

Johnson & Johnson MEA

Laura C. Coates

Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford

Stefan Siebert

School of Infection and Immunity, University of Glasgow